| |
|
HDV | Abstract Library |
 |
| |
| The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 5. | Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression |
| |
JHEP Rep. 2023 Apr 7;5(8):100751. doi: 10.1016/j.jhepr.2023.100751. eCollection 2023 Aug.
Mathias Jachs 1 2, Marlene Panzer 3, Lukas Hartl 1 2, Michael Schwarz 1 2, Lorenz Balcar 1 2, Jeremy V Camp 4, Petra Munda 1 2, Mattias Mandorfer 1 2, Michael Trauner 1 2, Stephan W Aberle 4, Heinz Zoller 3, Thomas Reiberger 1 2, Peter Ferenci 1
|
|
| |
| 6. | HDV RNA Assays: Performance characteristics, clinical utility and challenges |
| |
Hepatology. 2023 Aug 28. doi: 10.1097/HEP.0000000000000584. Online ahead of print.
Heiner Wedemeyer 1 2 3 4, Mitchell Leus 5, Thomas R Battersby 6, Jeffrey Glenn 7, Emmanuel Gordien 8, Saleem Kamili 9, Hema Kapoor 10, Harald H Kessler 11, Oliver Lenz 12, Marc Lütgehetmann 13 14, Tonya Mixson-Hayden 9, Christian O Simon 15, Michael Thomson 16, Gabriel Westman 17 18, Veronica Miller 5, Norah Terrault 19, Pietro Lampertico 20 21; HDV RNA Assays Writing Group at the HBV Forum
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 10. | HERACLIS-HDV cohort for the factors of underdiagnosis and prevalence of hepatitis D virus infection in HBsAg-positive patients |
| |
Liver Int. 2023 Sep;43(9):1879-1889. doi: 10.1111/liv.15638. Epub 2023 Jun 8.
George Papatheodoridis 1, Konstantinos Mimidis 2, Spilios Manolakopoulos 3, Christos Triantos 4, Ioannis Vlachogiannakos 1, Christos Veretanos 5, Melanie Deutsch 3, Stylianos Karatapanis 6, Ioannis Goulis 7, Ioannis Elefsiniotis 8, Evangelos Cholongitas 1, Vassilios Sevastianos 5, Dimitrios Christodoulou 9, Dimitrios Samonakis 10, Emanuel Manesis 11, Andreas Kapatais 12, Nikolaos Papadopoulos 3, Panagiota Ioannidou 1, Georgios Germanidis 13, George Giannoulis 14, Dimitra Lakiotaki 1, Dionysios Kogias 2, Ηarikleia Kranidioti 3, Konstantinos Zisimopoulos 4, Maria Mela 5, George Kontos 3, Paraskevi Fytili 1, Chrysanthi Manolaka 6, Polyxeni Agorastou 7, Spyridon I Pantzios 8, Margarita Papatheodoridi 1, Dimitrios Karagiannakis 1, Eleni Geladari 5, Nikolaos Psychos 9, Kalliopi Zachou 14, Anna Chalkidou 2, Anastasia Spanoudaki 3, Konstantinos Thomopoulos 4, George Dalekos 14
|
|
| |
|
|
| |
|
|
| |
| 13. | Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022 |
| |
JHEP Rep. 2023 Jun 28;5(9):100818. doi: 10.1016/j.jhepr.2023.100818.eCollection 2023 Sep.
Pietro Lampertico 1 2, Elisabetta Degasperi 1, Lisa Sandmann 3 4 5, Heiner Wedemeyer 3 4 5; Delta Cure 2022 Working Group
Collaborators
- Delta Cure 2022 Working Group:
Cihan Yurdaydin, Dominique Roulot, Fabien Zoulim, Florin Alexandru Caruntu, Heiner Wedemeyer, Helenie Kefalakes, Julie Lucifora, Kosh Agarwal, Laurent Castera, Maria Buti, Mario Rizzetto, Markus Cornberg, Maura Dandri, Maurizia Brunetto, Nancy Reau, Robert Gish, Saeed Hamid, Soo Aleman, Stephan Urban, Tarik Asselah, Thomas Berg, Victor de Lédinghen
|
|
| |
| 14. | A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D |
| |
N Engl J Med. 2023 Jul 6;389(1):22-32. doi: 10.1056/NEJMoa2213429.Epub 2023 Jun 22.
Heiner Wedemeyer 1, Soo Aleman 1, Maurizia Rossana Brunetto 1, Antje Blank 1, Pietro Andreone 1, Pavel Bogomolov 1, Vladimir Chulanov 1, Nina Mamonova 1, Natalia Geyvandova 1, Viacheslav Morozov 1, Olga Sagalova 1, Tatyana Stepanova 1, Annemarie Berger 1, Dmitry Manuilov 1, Vithika Suri 1, Qi An 1, Ben Da 1, John Flaherty 1, Anu Osinusi 1, Yang Liu 1, Uta Merle 1, Julian Schulze Zur Wiesch 1, Stefan Zeuzem 1, Sandra Ciesek 1, Markus Cornberg 1, Pietro Lampertico 1; MYR 301 Study Group
Collaborators
MYR 301 Study Group:
Pavel Bogomolov, Natalya Geyvandova, Sergey Zotov, Olga Sagalova, Viacheslav Morozov, Tatjana Stepanova, Vladimir Chulanov, Stefan Zeuzem, Heiner Wedemeyer, Antje Blank, Julian Schulze-Zur-Wiesch, Katharina Willuweit, Maurizia Brunego, Pietro Lampertico, Pietro Andreone, Stephen Urban
|
|
| |
|
|
| |
|
|
| |
| 17. | Advancing research, awareness, screening, and linkage to care to eliminate HDV in the U.S |
| |
Hepatol Commun. 2023 Jun 22;7(7):e00168. doi: 10.1097/HC9.0000000000000168.eCollection 2023 Jul 1.
Megan Glynn 1, Chari Cohen 2, Robert G Gish 3, Richard Andrews 4, Amy Trang 5, Beatrice Zovich 2, Warren Hall 6, Ryan Clary 7, Joseph Balestreri 8, Lori Scott 8, Rachel Scott 8, Tamika Jackson 9, Boatemaa Ntiri-Reid 10, Alia Southworth 11, Douglas Dieterich 12, Thomas Sepe 13
|
|
| |
|
|
| |
| 19. | Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial |
| |
Liver Int. 2023 Aug;43(8):1663-1676. doi: 10.1111/liv.15602.Epub 2023 May 15.
Katja Dinkelborg 1 2, Julia Kahlhöfer 1 3, Petra Dörge 1 3, Cihan Yurdaydin 4 5, Svenja Hardtke 3 6, Florin Alexandru Caruntu 7, Manuela G Curescu 8, Kendal Yalcin 9, Ulus S Akarca 10, Selim Gürel 11, Stefan Zeuzem 12, Andreas Erhardt 13, Stefan Lüth 6, George V Papatheodoridis 14, Onur Keskin 4, Kerstin Port 1, Monica Radu 7, Mustafa K Celen 9, Ramazan Idilman 4, Kristina Weber 15, Judith Stift 16, Ulrike Wittkop 17, Benjamin Heidrich 1 18 19, Ingmar Mederacke 1, Heiko von der Leyen 17, Hans Peter Dienes 16, Markus Cornberg 1 3 18 20, Armin Koch 15, Michael P Manns 1 18, Heiner Wedemeyer 1 18 19 21, Katja Deterding 1; HIDIT-2 Study Team
|
|
| |
| 20. | EASL Clinical Practice Guidelines on hepatitis delta virus |
| |
J Hepatol. 2023 Aug;79(2):433-460. doi: 10.1016/j.jhep.2023.05.001.Epub 2023 Jun 24.
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver
Collaborators
- Maurizia Rossana Brunetto, Gabriele Ricco, Francesco Negro, Heiner Wedemeyer, Cihan Yurdaydin, Tarik Asselah, George Papatheodoridis, Liana Gheorghe, Kosh Agarwal, Patrizia Farci, Maria Buti
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 25. | Farnesoid X receptor alpha ligands inhibit HDV in vitro replication and virion infectivity |
| |
Hepatol Commun. 2023 Apr 14;7(5):e0078. doi: 10.1097/HC9.0000000000000078.eCollection 2023 May 1.
Anne-Flore Legrand 1 2, Julie Lucifora 2 3, Benoît Lacombe 1, Camille Ménard 1, Maud Michelet 4, Adrien Foca 1, Pauline Abrial 1, Anna Salvetti 2, Michel Rivoire 5, Vincent Lotteau 1, David Durantel 2 3, Patrice André 1 2, Christophe Ramière 1 2 6
|
|
| |
|
|
| |
|
|
| |
| 28. | Hepatitis delta infection among persons living with HIV in Europe |
| |
Liver Int. 2023 Apr;43(4):819-828. doi: 10.1111/liv.15519. Epub 2023 Jan 21.
Charles Béguelin 1, Andrew Atkinson 1, Anders Boyd 2, Karolin Falconer 3, Nikolai Kirkby 4, Franziska Suter-Riniker 5, Huldrych F Günthard 6 7, Jürgen K Rockstroh 8, Amanda Mocroft 9 10, Andri Rauch 1, Lars Peters 10, Gilles Wandeler 1 11; for EuroSIDA and SHCS
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 32. | Strain-specific responsiveness of hepatitis D virus to interferon-alpha treatment |
| |
JHEP Rep. 2023 Jan 24;5(4):100673. doi: 10.1016/j.jhepr.2023.100673. eCollection 2023 Apr.
Katja Giersch 1, Paulina Perez-Gonzalez 1, Lennart Hendricks 1, Nora Goldmann 2, Jonathan Kolbe 1, Lennart Hermanussen 1, Jan-Hendrick Bockmann 1 3, Tassilo Volz 1, Annika Volmari 1, Lena Allweiss 1 3, Joerg Petersen 4, Dieter Glebe 2 3, Marc Lütgehetmann 3 5, Maura Dandri 1 3
|
|
| |
| 33. | No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta |
| |
J Hepatol. 2023 Apr 27;S0168-8278(23)00313-6. doi: 10.1016/j.jhep.2023.04.027.Online ahead of print.
Julius Hollnberger 1, Yang Liu 2, Simin Xu 3, Silvia Chang 3, Ross Martin 3, Savrina Manhas 3, Thomas Aeschbacher 3, Bin Han 3, Tahmineh Yazdi 3, Lindsey May 3, Dong Han 3, Alex Shornikov 3, John Flaherty 3, Dmitry Manuilov 3, Vithika Suri 3, Tarik Asselah 4, Pietro Lampertico 5, Heiner Wedemeyer 6, Soo Aleman 7, Christopher Richards 3, Roberto Mateo 3, Evguenia Maiorova 3, Tomas Cihlar 3, Hongmei Mo 3, Stephan Urban 8
|
|
| |
| 34. | Silent HDV epidemics culminates in high levels of liver cirrhosis in endemic region despite 20 years of HBV vaccination |
| |
J Viral Hepat. 2023 Mar;30(3):182-194. doi: 10.1111/jvh.13783. Epub 2022 Dec 27.
Olga V Isaeva 1 2, Karen K Kyuregyan 1 2 3, Anastasia A Karlsen 1 2 3, Oleg V Kuzmin 2, Ilya A Potemkin 1 2, Vera S Kichatova 1 2, Fedor A Asadi Mobarkhan 2, Eugeniy V Mullin 2, Tatyana V Kozhanova 4 5, Victor A Manuylov 6, Andrey A Pochtovyy 6, Vladimir A Gushchin 6, Anna A Saryglar 7, Lyudmila Yu Ilchenko 2 4, Mikhail I Mikhailov 1 2
|
|
| |
|
|
| |
| 36. | Hepatitis B virus and hepatitis D virus infection in women with or at risk for HIV infection in the United States |
| |
Front Med (Lausanne). 2023 Mar 2;10:1070420. doi: 10.3389/fmed.2023.1070420.eCollection 2023.
Ilona Argirion 1, Parag Mahale 1, Ruth M Pfeiffer 2, Ping Liu 3, Adaora A Adimora 4, Matthew J Akiyama 5 6, Hector H Bolivar 7, Audrey French 8 9, Michael Plankey 10, Jennifer C Price 11, Aadia Rana 12, Anandi Sheth 13 14, Jill Koshiol 1, Eric C Seaberg 15, Mark H Kuniholm 16, Jeffrey Glenn 3, Thomas R O'Brien 1
|
|
| |
| 37. | Treating hepatitis D with bulevirtide - Real-world experience from 114 patients |
| |
JHEP Rep. 2023 Mar 15;5(4):100686. doi: 10.1016/j.jhepr.2023.100686. eCollection 2023 Apr.
Christopher Dietz-Fricke 1, Frank Tacke 2, Caroline Zöllner 2, Münevver Demir 2, Hartmut H Schmidt 3, Christoph Schramm 3, Katharina Willuweit 3, Christian M Lange 4, Sabine Weber 4, Gerald Denk 4, Christoph P Berg 5, Julia M Grottenthaler 5, Uta Merle 6, Alexander Olkus 6, Stefan Zeuzem 7, Kathrin Sprinzl 7, Thomas Berg 8, Florian van Bömmel 8, Johannes Wiegand 8, Toni Herta 8, Thomas Seufferlein 9, Eugen Zizer 9, Nektarios Dikopoulos 9, Robert Thimme 10, Christoph Neumann-Haefelin 10, Peter R Galle 11, Martin Sprinzl 11, Ansgar W Lohse 12, Julian Schulze Zur Wiesch 12 13, Jan Kempski 12 14, Andreas Geier 15, Florian P Reiter 15, Bernhard Schlevogt 16, Juliana Gödiker 16, Wolf Peter Hofmann 17, Peter Buggisch 18, Julia Kahlhöfer 1, Kerstin Port 1, Benjamin Maasoumy 1, Markus Cornberg 1 19 20, Heiner Wedemeyer 1 21 22 19, Katja Deterding 1
|
|
| |
|
|
| |
| 39. | Treatment of chronic hepatitis d with peginterferon lambda - the phase 2 LIMT-1 clinical trial |
| |
Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000309. Online ahead of print.
Ohad Etzion 1 2, Saeed Hamid 3, Yoav Lurie 4, E J Gane 5, David Yardeni 1 2, Sarah Duehren 6, N Bader 3, Anat Nevo-Shor 1 2, S M Channa 7, S J Cotler 6, M Mawani 3, Om Parkash 3, Harel Dahari 6, Choong Ingrid 8, Jeffrey Glenn 9
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 43. | Hepatitis D virus interferes with hepatitis B virus RNA production via interferon-dependent and -independent mechanisms |
| |
J Hepatol. 2023 Jan 23;S0168-8278(23)00016-8. doi: 10.1016/j.jhep.2023.01.005.Online ahead of print.
Julie Lucifora 1, Dulce Alfaiate 2, Caroline Pons 3, Maud Michelet 4, Ricardo Ramirez 5, Floriane Fusil 6, Fouzia Amirache 6, Axel Rossi 7, Anne-Flore Legrand 6, Emilie Charles 6, Serena Vegna 4, Rayan Farhat 4, Michel Rivoire 8, Guillaume Passot 9, Nicolas Gadot 4, Barbara Testoni 4, Charlotte Bach 10, Thomas F Baumert 11, Anastasia Hyrina 5, Rudolf K Beran 5, Fabien Zoulim 12, Andre Boonstra 13, Hildegard Büning 7, Eloi R Verrier 10, François-Loïc Cosset 6, Simon P Fletcher 5, Anna Salvetti 6, David Durantel 3
|
|
| |
|
|
| |
| 45. | Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension |
| |
J Hepatol. 2022 Dec;77(6):1525-1531. doi: 10.1016/j.jhep.2022.07.016. Epub 2022 Aug 13.
Elisabetta Degasperi 1, Maria Paola Anolli 1, Sara Colonia Uceda Renteria 2, Dana Sambarino 1, Marta Borghi 1, Riccardo Perbellini 1, Caroline Scholtes 3, Floriana Facchetti 1, Alessandro Loglio 1, Sara Monico 1, Mirella Fraquelli 4, Andrea Costantino 4, Ferruccio Ceriotti 2, Fabien Zoulim 3, Pietro Lampertico 5
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 55. | Hepatitis D virus infection in a large cohort of immigrants in southern Italy: a multicenter, prospective study |
| |
Infection. 2022 Oct 12;1-8. doi: 10.1007/s15010-022-01938-0. Online ahead of print.
Pisaturo Mariantonietta 1 2, Alessio Loredana 1 3, Di Fraia Alessandra 1, Macera Margherita 1 4, Minichini Carmine 1, Cordua Emanuele 1, Onorato Lorenzo 1 5, Scotto Gaetano 6 7, Di Caprio Giovanni 2 8, Calò Federica 1 4, Sagnelli Caterina 1 5, Coppola Nicola 9
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 59. | Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial |
| |
Lancet Infect Dis. 2022 Sep 13;S1473-3099(22)00318-8. doi: 10.1016/S1473-3099(22)00318-8.Online ahead of print.
Heiner Wedemeyer 1, Katrin Schöneweis 2, Pavel Bogomolov 3, Antje Blank 4, Natalia Voronkova 5, Tatiana Stepanova 6, Olga Sagalova 7, Vladimir Chulanov 8, Marina Osipenko 9, Viacheslav Morozov 10, Natalia Geyvandova 11, Snezhana Sleptsova 12, Igor G Bakulin 13, Ilsiyar Khaertynova 14, Marina Rusanova 15, Anita Pathil 16, Uta Merle 17, Birgit Bremer 18, Lena Allweiss 19, Florian A Lempp 20, Kerstin Port 18, Mathias Haag 21, Matthias Schwab 22, Julian Schulze Zur Wiesch 19, Markus Cornberg 18, Walter E Haefeli 4, Maura Dandri 19, Alexander Alexandrov 23, Stephan Urban 24
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 63. | Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections |
| |
Gut. 2022 Aug 17;gutjnl-2022-327216. doi: 10.1136/gutjnl-2022-327216. Online ahead of print.
Rani Burm 1, Panagiota Maravelia 2, Gustaf Ahlen 2, Sandra Ciesek 3 4 5, Noelia Caro Perez 2, Anna Pasetto 2, Stephan Urban 6, Freya Van Houtte 1, Lieven Verhoye 1, Heiner Wedemeyer 7, Magnus Johansson 8, Lars Frelin 2, Matti Sällberg 9, Philip Meuleman 10
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 75. | Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-Results of A "real world" Study |
| |
Aliment Pharmacol Ther. 2022 May 5. doi: 10.1111/apt.16945. Online ahead of print.
Mathias Jachs 1 2, Caroline Schwarz 3, Marlene Panzer 4, Teresa Binter 1 2, Stephan W Aberle 5, Lukas Hartl 1 2, Kristina Dax 6, Elmar Aigner 7, Albert F Stättermayer 1 2, Petra Munda 1, Ivo Graziadei 8, Heidemarie Holzmann 5, Michael Trauner 1 2, Heinz Zoller 4, Michael Gschwantler 3, Mattias Mandorfer 1 2, Thomas Reiberger 1 2, Peter Ferenci 1
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 80. | Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification |
| |
Biomedicines. 2022 Mar 29;10(4):792. doi: 10.3390/biomedicines10040792.
Antonella Olivero 1 2, Chiara Rosso 1, Alessia Ciancio 1 2, Maria Lorena Abate 1 2, Aurora Nicolosi 1, Giulia Troshina 1, Angelo Armandi 1, Davide Giuseppe Ribaldone 1 2, Giorgio Maria Saracco 1 2, Elisabetta Bugianesi 1 2, Mario Rizzetto 1, Gian Paolo Caviglia 1
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 84. | Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis |
| |
United European Gastroenterol J. 2021 Dec;9(10):1119-1127.doi: 10.1002/ueg2.12163. Epub 2021 Dec 7.
Mathias Jachs 1 2, Teresa Binter 1 2, Caroline Schmidbauer 2 3, Lukas Hartl 1 2, Michael Strasser 4, Hermann Laferl 5, Stephanie Hametner-Schreil 6, Alexander Lindorfer 6, Kristina Dax 7, Rudolf E Stauber 8, Harald H Kessler 9, Sebastian Bernhofer 10, Andreas Maieron 10, Lorin Loacker 11, Simona Bota 12, Isabel Santonja 13, Petra Munda 1, Mattias Mandorfer 1 2, Markus Peck-Radosavljevic 12, Heidemarie Holzmann 13, Michael Gschwantler 2 3, Heinz Zoller 14, Peter Ferenci 1, Thomas Reiberger 1 2
|
|
| |
|
|
| |
|
|
| |
| 87. | Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis |
| |
United European Gastroenterol J. 2021 Dec;9(10):1119-1127.doi: 10.1002/ueg2.12163. Epub 2021 Dec 7.
Mathias Jachs 1 2, Teresa Binter 1 2, Caroline Schmidbauer 2 3, Lukas Hartl 1 2, Michael Strasser 4, Hermann Laferl 5, Stephanie Hametner-Schreil 6, Alexander Lindorfer 6, Kristina Dax 7, Rudolf E Stauber 8, Harald H Kessler 9, Sebastian Bernhofer 10, Andreas Maieron 10, Lorin Loacker 11, Simona Bota 12, Isabel Santonja 13, Petra Munda 1, Mattias Mandorfer 1 2, Markus Peck-Radosavljevic 12, Heidemarie Holzmann 13, Michael Gschwantler 2 3, Heinz Zoller 14, Peter Ferenci 1, Thomas Reiberger 1 2
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 93. | A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection |
| |
Viruses. 2021 Nov 26;13(12):2371. doi: 10.3390/v13122371.
Florian A Lempp 1 2, Imme Roggenbach 1, Shirin Nkongolo 1 2 3, Volkan Sakin 1, Franziska Schlund 1, Paul Schnitzler 4, Heiner Wedemeyer 5, Frédéric Le Gal 6, Emmanuel Gordien 6, Cihan Yurdaydin 7 8, Stephan Urban 1 2
|
|
| |
| 94. | Novel Therapies of Hepatitis B and D |
| |
Microorganisms. 2021 Dec 17;9(12):2607. doi: 10.3390/microorganisms9122607.
Iman Waheed Khan 1, Mati Ullah Dad Ullah 1, Mina Choudhry 1, Mukarram Jamat Ali 1, Muhammad Ashar Ali 1, Sam L K Lam 2, Pir Ahmad Shah 3, Satinder Pal Kaur 1, Daryl T Y Lau 1
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 99. | The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response? |
| |
Arch Public Health. 2021 Oct 19;79(1):180. doi: 10.1186/s13690-021-00693-2.
Tomoyuki Hayashi 1 2, Yumie Takeshita 3 4, Yvan J-F Hutin 3, Hande Harmanci 3, Philippa Easterbrook 3, Sarah Hess 3, Judith van Holten 3, Ena Oghenekaro Oru 3, Shuichi Kaneko 4, Cihan Yurdaydin 5 6, Marc Bulterys 3
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 103. | The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease |
| |
J Adv Res. 2021 Mar 2;33:183-187. doi: 10.1016/j.jare.2021.02.009. eCollection 2021 Nov.
Gian Paolo Caviglia 1, Silvia Martini 2, Alessia Ciancio 1 2, Grazia Anna Niro 3, Antonella Olivero 1, Rossana Fontana 3, Francesco Tandoi 4, Chiara Rosso 1, Renato Romagnoli 4 5, Giorgio Maria Saracco 1 2, Antonina Smedile 1 2, Mario Rizzetto 1 2
|
|
| |
|
|
| |
| 105. | A Mathematical Analysis of HDV Genotypes: From Molecules to Cells |
| |
Mathematics (Basel). 2021 Sep 1;9(17):2063. doi: 10.3390/math9172063. Epub 2021 Aug 26.
Rami Zakh 1, Alexander Churkin 2, Franziska Totzeck 3, Marina Parr 3, Tamir Tuller 4, Ohad Etzion 5, Harel Dahari 6, Michael Roggendorf 7, Dmitrij Frishman 3, Danny Barash 1
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 114. | One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease |
| |
Aliment Pharmacol Ther. 2021 Jun 28. doi: 10.1111/apt.16485. Online ahead of print.
Adriana Palom 1 2, Sara Sopena 3, Mar Riveiro-Barciela 1 2 4, Angela Carvalho-Gomes 4 5, Antonio Madejón 4 6, Sergio Rodriguez-Tajes 4 7, Luisa Roade 1 2 4, María García-Eliz 5, Javier García-Samaniego 4 6, Sabela Lens 4 7, Marina Berenguer-Hayme 4 5, Francisco Rodríguez-Frías 2 3 4, Helena Hernandez-Évole 5, Ana Isabel Gil-García 4 6, Ana Barreira 1 2 4, Rafael Esteban 1 2 4, Maria Buti 1 2 4
|
|
| |
|
|
| |
| 116. | HDV-Like Viruses |
| |
Viruses. 2021 Jun 23;13(7):1207. doi: 10.3390/v13071207.
Jimena Pérez-Vargas 1, Rémi Pereira de Oliveira 1, Stéphanie Jacquet 2, Dominique Pontier 2, François-Loïc Cosset 1, Natalia Freitas 1
|
|
| |
| 117. | Update on the management and treatment of viral hepatitis |
| |
World J Gastroenterol. 2021 Jun 21;27(23):3249-3261.doi: 10.3748/wjg.v27.i23.3249.
Patricia Holanda Almeida 1, Celso E L Matielo 1, Lilian A Curvelo 1, Rodrigo A Rocco 1, Guilherme Felga 1, Bianca Della Guardia 1, Yuri L Boteon 1
|
|
| |
|
|
| |
| 119. | New therapies for hepatitis delta virus infection |
| |
Liver Int. 2021 Jun;41 Suppl 1:30-37. doi: 10.1111/liv.14838.
Dimitri Loureiro 1 2, Corinne Castelnau 1 2, Issam Tout 1 2, Nathalie Boyer 1 2, Stéphanie Narguet 1 2, Sabrina Menasria Benazzouz 1 2, Zeina Louis 1 3, Nathalie Pons-Kerjean 1 3, Nathalie Giuly 1 2, Patrick Marcellin 1 2, Abdellah Mansouri 1 2, Tarik Asselah 1 2
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 130. | Current status of hepatitis delta |
| |
Curr Opin Pharmacol. 2021 Apr 22;58:62-67. doi: 10.1016/j.coph.2021.03.008.Online ahead of print.
Margarita Papatheodoridi 1, George V Papatheodoridis 2
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 137. | Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection |
| |
Hepatol Commun. 2020 Nov 13;5(2):189-202. doi: 10.1002/hep4.1633. eCollection 2021 Feb.
Michel Bazinet 1, Victor Pântea 2, Valentin Cebotarescu 2, Lilia Cojuhari 2, Pavlina Jimbei 3, Mark Anderson 4, Jeff Gersch 4, Vera Holzmayer 4, Carina Elsner 5, Adalbert Krawczyk 5 6, Mary C Kuhns 4, Gavin Cloherty 4, Ulf Dittmer 5, Andrew Vaillant 1
|
|
| |
| 138. | The changing scenario of hepatitis D |
| |
J Hepatol. 2021 Jan 20;S0168-8278(21)00023-4. doi: 10.1016/j.jhep.2021.01.014.Online ahead of print.
Mario Rizzetto 1, Saeed Hamid 2, Franco Negro 3
|
|
| |
| 139. | |
| |
Oxf Med Case Reports. 2020 Oct 23;2020(10):omaa084.doi: 10.1093/omcr/omaa084. eCollection 2020 Oct.
Meha Bhuva 1, Marie Moore 1, Sambit Sen 1
|
|
| |
|
|
| |
|
|
| |
| 142. | Residual low HDV viremia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study |
| |
Liver Int. 2020 Nov 20. doi: 10.1111/liv.14740. Online ahead of print.
Birgit Bremer 1, Olympia Anastasiou 2, Svenja Hardtke 3 4, Florin Alexandru Caruntu 5, Manuela G Curescu 6, Kendal Yalcin 7, Ulus S Akarca 8, Selim Gürel 9, Stefan Zeuzem 10, Andreas Erhardt 11, Stefan Lüth 12, George V Papatheodoridis 13, Monica Radu 5, Ramazan Idilman 14, Michael P Manns 1 4, Markus Cornberg 1 4, Cihan Yurdaydin 14 15, Heiner Wedemeyer 1 4 16
|
|
| |
|
|
| |
|
|
| |
| 145. | Viral hepatitis and pregnancy |
| |
Nat Rev Gastroenterol Hepatol. 2020 Oct 12. doi: 10.1038/s41575-020-00361-w.Online ahead of print.
Norah A Terrault 1, Miriam T Levy 2, Ka Wang Cheung 3, Gonzague Jourdain 4 5
|
|
| |
| 146. | Bulevirtide: First Approval |
| |
Drugs. 2020 Sep 14.doi: 10.1007/s40265-020-01400-1. Online ahead of print.
Connie Kang 1, Yahiya Y Syed 2
|
|
| |
|
|
| |
| 148. | Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta |
| |
J Viral Hepat. 2020 Jul 24. doi: 10.1111/jvh.13366. Online ahead of print.
Anika Wranke 1, Svenja Hardtke 1 2, Benjamin Heidrich 1 2, George Dalekos 3, Kendal Yalcin 4, Fehmi Tabak 5, Selim Gurel 6, Yilmaz Cakaloglu 7, Ulus S Akarca 8, Frank Lammert 9, Dieter Häussinger 10, Tobias Müller 11, Michael Wöbse 1, Michael P Manns 1 2, Ramazan Idilman 12, Markus Cornberg 1 2, Heiner Wedemeyer 2 13, Cihan Yurdaydin 12 14
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 157. | Migratory Flow and Hepatitis Delta Infection in Italy: A New Challenge at the Beginning of the Third Millennium |
| |
Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13310. Online ahead of print.
Tommaso Stroffolini 1, Alessia Ciancio 2, Caterina Furlan 1, Maria Vinci 3, Rosanna Fontana 4, Maurizio Russello 5, Guido Colloredo 6, Filomena Morisco 7, Nicola Coppola 8 9, Sergio Babudieri 10, Luigina Ferrigno 11, Caterina Sagnelli 9, Evangelista Sagnelli 9
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 161. | Long-term study of hepatitis D infection at secondary care centers: the impact of viremia on liver-related outcomes |
| |
Kamal H1,2, Westman G3, Falconer K1,2, Duberg AS4, Weiland O1,2, Haverinen S1, Wejstål R5, Carlsson T6, Kampmann C7, Larsson S8, Björkman P9, Nystedt A10, Cardell K10, Svensson S11, Stenmark S12, Wedemeyer H13, Aleman S1,2. Hepatology. 2020 Mar 7. doi: 10.1002/hep.31214. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
| 164. | Future treatments for hepatitis delta virus infection |
| |
Asselah T1,2, Loureiro D1,2, Tout I1,2, Castelnau C1,2, Boyer N1,2, Marcellin P1,2, Mansouri A1,2. Liver Int. 2020 Feb;40 Suppl 1:54-60. doi: 10.1111/liv.14356.
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 168. | High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort |
| |
Bockmann JH1,2, Grube M3, Hamed V3, von Felden J3, Landahl J3, Wehmeyer M3, Giersch K3, Hall MT4,5, Murray JM4,5, Dandri M3,6, Lüth S3,7, Lohse AW3,6, Lütgehetmann M3,8, Schulze Zur Wiesch J3,6. BMC Gastroenterol. 2020 Jan 30;20(1):24. doi: 10.1186/s12876-020-1168-9.
|
|
| |
|
|
| |
|
|
| |
| 171. | Estimating the global prevalence, disease progression and clinical outcome of hepatitis delta virus infection |
| |
Miao Z1, Zhang S1, Ou X1, Li S1,2, Ma Z3, Wang W1,4, Peppelenbosch MP1, Liu J1, Pan Q1. J Infect Dis. 2019 Nov 28. pii: jiz633. doi: 10.1093/infdis/jiz633. [Epub ahead of print]
|
|
| |
|
|
| |
| 173. | HDV infection in immigrant populations |
| |
Coppola N1,2, Alessio L2, Onorato L1, Sagnelli C1,2, Sagnelli E1, Pisaturo M1. J Med Virol. 2019 Dec;91(12):2049-2058. doi: 10.1002/jmv.25570. Epub 2019 Aug 27.
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 177. | We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade |
| |
Lazarus JV1, Pericàs JM2, Picchio C1, Cernosa J3, Hoekstra M1, Luhmann N4, Maticic M5,6, Read P7, Robinson EM8, Dillon JF8. J Intern Med. 2019 Aug 31. doi: 10.1111/joim.12972. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 181. | Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial |
| |
Wedemeyer H1, Yurdaydin C2, Hardtke S3, Caruntu FA4, Curescu MG5, Yalcin K6, Akarca US7, Gürel S8, Zeuzem S9, Erhardt A10, Lüth S11, Papatheodoridis GV12, Keskin O13, Port K14, Radu M4, Celen MK6, Idilman R13, Weber K15, Stift J16, Wittkop U17, Heidrich B3, Mederacke I14, von der Leyen H18, Dienes HP16, Cornberg M14, Koch A15, Manns MP19; HIDIT-II study team. Lancet Infect Dis. 2019 Mar;19(3):275-286. doi: 10.1016/S1473-3099(18)30663-7.
|
|
| |
| 182. | Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy |
| |
Yurdaydin C1, Abbas Z2, Buti M3, Cornberg M4, Esteban R3, Etzion O5, Gane EJ6, Gish RG7, Glenn JS7, Hamid S8, Heller T9, Koh C9, Lampertico P10, Lurie Y11, Manns M4, Parana R12, Rizzetto M13, Urban S14, Wedemeyer H15; Hepatitis Delta International Network (HDIN). J Hepatol. 2019 May;70(5):1008-1015. doi: 10.1016/j.jhep.2018.12.022. Epub 2018 Dec 27.
|
|
| |
| 183. | Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells |
| |
Dias J1, Hengst J2, Parrot T1, Leeansyah E3, Lunemann S4, Malone DFG1, Hardtke S5, Strauss O1, Zimmer CL1, Berglin L1, Schirdewahn T5, Ciesek S6, Marquardt N1, von Hahn T5, Manns MP5, Cornberg M5, Ljunggren HG1, Wedemeyer H7, Sandberg JK1, Björkström NK8. J Hepatol. 2019 Aug;71(2):301-312. doi: 10.1016/j.jhep.2019.04.009. Epub 2019 May 14.
|
|
| |
|
|
| |
|
| |
|
|
|
|
|
Stay Informed!
